Haleon (HLN) Intangibles (2021 - 2026)

Haleon's (HLN) quarterly Intangibles came in at $34.5 billion in Q2 2026, up 0.66% on a QoQ basis from $34.3 billion in Q4 2025.

Haleon (HLN) Intangibles (2021 - 2026) Analysis & Trends

Haleon (HLN) has 6 years of Intangibles data on file, last reported at $34.5 billion in Q2 2026.

Quarterly Intangibles changed N/A year-over-year to $34.5 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $34.5 billion (changed N/A YoY) and the FY2025 annual result came in at $34.1 billion, up 1.69% from the prior year.
Intangibles rose to $34.5 billion in Q2 2026, from $34.3 billion in the prior quarter.
In the past five years, Intangibles ranged from a high of $35.9 billion in Q2 2022 to a low of $33.3 billion in Q2 2024.
A 5-year average of $34.3 billion and a median of $34.3 billion in 2023 frame the typical range for Intangibles.
Annual changes were most pronounced in 2022 — Intangibles decreased 8.75% — and 2025, when it grew 2.01%.
Tracing HLN's Intangibles over 5 years: stood at $34.1 billion in 2022, then advanced by 0.2% to $34.2 billion in 2023, then retreated by 1.6% to $33.6 billion in 2024, then gained by 2.01% to $34.3 billion in 2025, then gained by 0.66% to $34.5 billion in 2026.
The last three Intangibles figures came in at $34.5 billion (Q2 2026), $34.3 billion (Q4 2025), and $33.6 billion (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Haleon	43.94 Bn	42.97 Bn	-	-
2	Teva Pharmaceutical Industries	43.08 Bn	39.43 Bn	2.15 Bn	3.45 Bn
3	Zoetis	31.54 Bn	29.87 Bn	1.05 Bn	918.00 Mn
4	Takeda Pharmaceutical	28.60 Bn	22.80 Bn	5.10 Bn	21.28 Bn
5	United Therapeutics	22.12 Bn	19.46 Bn	683.80 Mn	-
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn	13.68 Bn
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn	2.23 Bn
8	Elanco Animal Health	11.69 Bn	11.16 Bn	798.00 Mn	3.20 Bn
9	Dr Reddys Laboratories	10.13 Bn	9.96 Bn	-	1.12 Bn
10	Alkermes	8.09 Bn	7.43 Bn	397.90 Mn	1.80 Bn

Download Data